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Abstract: Fluoropyrimidines and oxaliplatin continued to be the mainstay of therapeutic regimens in the treatment of colorectal cancer 
(CRC). For this reason, pharmacokinetic and metabolism of these drugs were analyzed and the identification of accurate and validated 
predictive, prognostic and toxicity markers became necessary to develop an effective therapy adapted to the patient’s molecular profile, 
while minimizing life-threatening toxicities. In this review, we discuss literature data, defining predictive and prognostic markers actually 
identified in the treatment of CRC. We analyzed predictive markers of fluoropyrimidines effectiveness, principally for 5-Fluorouracil (5-
FU) and also for oral fluoropyrimidines, as thymidylate Synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl 
transferase (OPRT), methylenetetrahydrofolate reductase (MTHFR), deoxyuridine triphosphate nucleotidohydrolase (dUTPase), micro-
satellite instability. DPD represent the more studied 5-FU toxicity marker, followed by TS and OPRT. Oxaliplatin effectiveness is princi-
pally regulated by nucleotide excision repair (NER) pathway, including excision repair cross-complementation group 1 (ERCC1), X-ray 
cross-complementing group 1 (XRCC1) and xeroderma pigmentosum group D (XDP). The major oxaliplatin toxicity marker is repre-
sented by glutathione S-transferase (GST). All these results are based principally on retrospective studies. The future challenge became to 
validate molecular markers and their association with clinical outcomes in prospective trials, refining technologic platforms and bioin-
formatics to accommodate the complexity of the multifaceted molecular map that may determine outcome, and determining CRC patients 
most likely to benefit from therapeutic interventions tailored specifically for them. 
Keywords: 5-Fluorouracil, dihydropyrimidine dehydrogenase, glutathione S-transferase, nucleotide excision repair, oxaliplatin, predictive 
marker, thymidylate synthase, toxicity marker. 
1. INTRODUCTION 
 From several years research on a global scale has attempted to 
define subsets of biochemical markers that may be useful predictors 
of response to treatment, in particular evaluating clinical response, 
toxicity, and time to disease progression, prognostic markers to de-
termine the aggressiveness of the disease and the likelihood of re-
currence after surgery. Also pharmacogenomics is emerging as an 
increasingly useful molecular tool to investigate the drugs efficacy 
by analysis of patient variables (i.e. genetic polymorphisms, meta-
bolizing enzymes, transporters). For this reason, the identification 
of accurate and validated predictive and prognostic markers will 
provide the clinician with the knowledge and the means of tailoring 
a targeted and effective therapy to the patient’s molecular profile 
while minimizing life-threatening toxicities. 
2. FLUOROPYRIMIDINES: 5-FLUOROURACIL (5-FU) 
 Since its introduction in 1957, the fluoropyrimidine 5-FU has 
been the mainstay of therapeutic regimens in the treatment of CRC. 
Several steps are present in its complex pharmacokinetic. Upon en-
try to the cell, 5-FU is converted to its active metabolite, 5-fluoro-2-
deoxyuridine monophosphate (FdUMP), whose primary mechanism 
of action is inhibition of thymidylate synthase (TS) by formation of 
a ternary complex. This blocks the de novo synthesis of thymidine, 
essential component for DNA synthesis, and initiates DNA damage 
(Fig. 1) [1]. 
2.1. Predictive Markers of 5-FU Effectiveness  
 Adjuvant treatment with 5-FU has been shown to improve the 
absolute survival rate of stage III colon carcinoma patients by  
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~10%–15%. Increasing evidence indicates that stage II CRC pa-
tients also gain benefit from 5-FU-based therapies [2]. Because 
only a relatively small proportion of patients appear to benefit from 
this treatment, considerable effort has been directed towards finding 
biomarkers that can accurately predict tumour response [1]. These 
have included initially molecular factors such as microsatellite in-
stability [3] and chromosomal deletions [4], subsequently de-
scribed. 
 There is, however, currently insufficient evidence to justify the 
incorporation of these or any other candidate predictive markers 
into routine clinical practice for the selection of CRC patients to 
receive 5-FU. In this condition, the levels of TS expression became 
a strong candidate marker for the prediction of 5-FU response [5].  
2.1.1. Thymidylate Synthase (TS) in CRC patients treated with 5-
FU 
 A significant number of studies initially have correlated intra-
tumoral TS levels with response to fluoropyrimidine-based therapy 
[6-8]. The study by Salonga et al. demonstrated for the first time 
that patients with CRC who responded to 5-FU therapy could be 
segregated by analysis of three genes in the 5-FU pathway. Those 
patients with low expression levels of TS, thymidine phosphorylase 
(TP), and dihydropyrimidine dehydrogenase (DPD) (these last two 
factors implicated also in 5-FU metabolism) all responded, and 
those with elevated expression in at least one of the three genes did 
not [8]. It is unclear whether this occurs because such tumours have 
better prognosis or they are more sensitive to 5-FU treatment. The 
success of these preliminary studies conducted to the analysis by 
Kornmann M et al. [9]. In this Germany study, an mRNA quantiza-
tion technique using real-time RT-PCR and determining TS and 
DPD levels from paraffin-embedded primary CRC tissue sections 
was used. Patients with colon cancer UICC stage IIb (T4pN0) and 
III (pT1–4pN positive) and patients with rectal cancer UICC stage 
II (pT3–4pN0) and III (pT1–4pN positive) receiving adjuvant 5-
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FU-based chemotherapy who participated in FOGT-1 colon (i.v. 5-
FU 450 mg/m2 in 60–120 min weekly) in combination with oral 
levamisol (3 x 50 mg/day for 3 days every 14 days for a total of 1 
year) or FOGT-2 rectal cancer (FOGT-1 plus postoperative radia-
tion of the pelvis with 50.4 Gy) trial were enrolled. The results ex-
plain that longer disease free survival was correlated with low lev-
els of DPD and surprisingly with high levels of TS, while the TS 
and DPD levels were identified as not important prognostic factors 
for tumor recurrence. In conclusion, TS and DPD play key roles in 
5-FU resistance, and intratumoral TS mRNA level for the first time 
appeared to be a prognostic marker for disease-specific survival. 
Several other larger studies, as described by Edler D et al, have 
concluded that elevated TS levels are more likely to benefit from 5- 
FU–based chemotherapy [10].  
 While Salonga et al. used tumour response and disease-specific 
survival evaluating mRNA levels of predictive factors, Soong R et 
al. analyzed the associations between TS, DPD and TP protein lev-
els, determined by tissue microarrays and immunohistochemistry, 
and survival in 945 CRC patients according to treatment status [11]. 
The results showed that low TS and DPD expression were associ-
ated with worse prognosis in stage II (HR 1.69 and 1.92, respec-
tively) and stage III CRC patients treated by surgery alone (HR 
1.39 and HR 1.49, respectively). No correlation was demonstrated 
with TP levels. Low TS, DPD and TP were associated with trends 
for better outcome in stage III patients treated with 5-FU (HR 0.81, 
0.70 and 0.66, respectively]. These results confirmed that low TS 
and DPD expression were prognostic for worse outcome in CRC 
patients treated by surgery alone, whereas low TS, DPD and TP 
expression are prognostic for better outcome in patients treated with 
5-FU chemotherapy. On these basis, we can presuppose that the 
results proven by Soong R and colleagues can provide an indirect 
evidence that low expression of all three proteins are predictive of 
good response to 5-FU chemotherapy. A possible explanation for 
these conflicting observations is that TS levels detected by immu-
nohistochemistry (IHC) can demonstrate significant variation as a 
result of antibody specificity and tissue handling/preparation. For 
this reason, TS became the 5-FU pathway that is more studied 
around all the last 15 years. Several subsequently studies have ana-
lyzed is role as prognostic and predictive factor for CRC treated 
with 5-FU and derivates.  
 The greater meta-analysis was performed by Popat et al. [12], 
which analyzed 20 studies of over 3,000 patients, stratifying overall 
survival and/or progression-free survival in CRC patients by TS 
expression status. The principal examined outcome measure was 
the Hazard Ratio (HR). Thirteen studies of 30 investigated outcome 
in a total of 887 cases with advanced CRC, and seven studies inves-
tigated outcome in a total of 2.610 patients with localized CRC. A 
number of methods were used both to assess TS expression and to 
assign TS status. Methods used to determine TS expression and as-
sign expression status were IHC, reverse transcriptase polymerase 
chain reaction (RTPCR), and enzyme assay. The median proportion 
of cases expressing high TS levels was similar in both advanced 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Mechanisms of action of 5-FU. 
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and adjuvant settings; 53% (range, 14%- 80%) and 50% (range, 
19%-77%, respectively. The combined HR estimate for overall sur-
vival (OS) was 1.74 (95% CI, 1.34 to 2.26) and 1.35 (95% CI, 1.07 
to 1.80) in the advanced and adjuvant settings, respectively, but 
there was evidence of important heterogeneity among these data. 
Restricting analysis to the three eligible studies in which patients 
received surgery only, the pooled HRs were 1.92 (95% CI, 1.12 to 
3.32) and 1.90 (95% CI, 1.35 to 2.67) for OS and Progression Free 
Survival (PFS), respectively. On the other hand, evaluating studies 
in which patients received surgery and adjuvant 5-FU chemother-
apy, the pooled HRs for OS and PFS were 0.93 (95% CI, 0.69 to 
1.24) and 1.00 (95% CI, 0.92 to 1.08), respectively. However, these 
results, for the authors, should be interpreted with caution due to the 
small number of contributing studies. There was the evidence of 
many publication biases, including heterogeneity between studies 
(sample sizes varied greatly), unclear optimal method of assessing 
TS expression and many number of differing scoring methods 
used. These results can demonstrate that in patients with both local 
and advanced CRC, TS expression is predictive for survival. TS 
retains its prognostic significance whether expression is measured 
from metastasis or primary CRC. In patients treated with both sur-
gery and adjuvant 5-FU, TS expression does not seem to predict 
outcome. The final result of the study is that CRC patients with ele-
vated TS expression demonstrated poorer overall survival compared 
with those whose tumors expressed low levels [12].  
 We are agree with the authors of this metanalysis, when they 
suggest that several small and early studies report a positive rela-
tionship between high TS levels and poor prognosis, while the cor-
responding subsequent larger studies fail to replicate these data. 
However, it is actually accepted the hypothesis that variation in 
TS expression is a determinant of prognosis and it is an attrac-
tive mechanism for explaining any inter-individual variation in 
clinical outcome after fluoropyrimidines therapy. 
 After these evidences, proving the determinant and critical role 
of regulation of TS expression for the efficacy of fluoropyrimidi-
nes, therefore identifying genetic alterations that regulate TS gene 
expression could became crucial for developing predictive markers. 
Functional genomic polymorphisms have been demonstrated, inter-
esting within the 5 region and the 3-UTR of the TS gene [13]. The 
5 polymorphic variant results in the majority of patients possessing 
a series of 28bp repeats termed TS2R (2 repeats) or TS3R (3 re-
peats). TS2R is associated with lower TS enzyme expression in vi-
tro and in vivo and has been associated with increased clinical bene-
fit in fluoropyrimidine treatment. Conversely, the 3R/3R genotype 
has been associated with increased TS mRNA expression, a signifi-
cantly reduced response rate, and increased toxicity during 5-FU 
therapy [14]. Subsequently, additional polymorphisms within this 
28bp repeat have been identified. Mandola et al described a G–C 
nucleotide transition located only in the TS3R allele, which disrupts 
transacting factors from binding a functional E-Box element and 
leads to reduced TS mRNA expression [15]. 
 All these experiences show the possibility that an elevated level 
of TS alone is unlikely to be sufficient to predict response to 5-FU. 
A subset of patients with low TS expression do not respond to 5-
FU–based therapy and may have additional mechanisms of resis-
tance explained by modulation of other 5-FU–metabolizing en-
zymes, such as dihydropyrimidine dehydrogenase (DPD), methyle-
netetrahydrofolate reductase (MTHFR), orotate phosphoribosyl 
transferase (OPRT), and deoxyuridine triphosphate nucleotidohy-
drolase (dUTPase). 
2.1.2. Dihydropyrimidine Dehydrogenase (DPD) in CRC Patients 
Treated with 5-FU 
 DPD catalyses the rate-limiting step in the catabolism of 
fluoropyrimidines with more than 80% of 5-FU administered de-
graded by DPD in the liver. Variation in expression levels of DPD 
therefore has a direct effect on the bioavailability of 5-FU and its 
role, principally in the toxicity of therapy, as described subse-
quently. However, DPD has demonstrated also a prognostic signifi-
cance in several studies. It was demonstrated that patients with 
DPD low expression had longer disease-free recurrence and in-
creased survival than those with high expression [16, 17]. However, 
its role in predicting response to 5-FU is complicated by widely 
variable expression levels in tumor and normal tissues, as expressed 
in the study of van Kuilenburg et al. [18].  
2.1.3. Orotate Phosphoribosyl Transferase (OPRT) in CRC Pa-
tients Treated with 5-FU 
 Additional enzymes involved in fluoropyrimidine metabolism 
have been implicated in determining drug sensitivity, including 
OPRT, the enzyme catalyzing the reduction of FUDP to the active 
metabolite FdUMP which irreversibly binds to TS. Ichikawa W et 
al. in their study directly linked OPRT expression to 5-FU sensitiv-
ity, concluding that increased OPRT mRNA expression (P=.0008) 
and high OPRT/DPD mRNA ratio (P = .003) predicted response to 
fluoropyrimidine- based therapy in a small cohort of patients with 
metastatic CRC [19]. In a more recent revaluation, Ishikawa et al. 
investigated TS, DPD and OPRT activities and their association 
with clinicopathological variables in cancer tissue and adjacent 
normal tissue from 40 CRC patients who had undergone curative 
surgery and were orally administered adjuvant tegafur/uracil (UFT) 
chemotherapy. While there was no evidence of clear relationship 
between pathological findings and TS or DPD activity, the authors 
concluded that OPRT activity was significantly lower in tumors 
with lymph node metastasis than in tumors lacking lymph node me-
tastasis (with P<0.01). Postoperative survival was significantly bet-
ter in the groups with low TS activity and/or high OPRT activity 
[20]. 
 This result open the possibility that OPRT activity levels in tu-
mor tissue may be important prognostic factors for survival in 
Dukes' B and C CRC with radical resection and adjuvant chemo-
therapy with UFT. Really, these conclusions are drawn from a lim-
ited retrospective study. The limit of this study can also be ex-
plained by bias patients and treatment data. Patients enrolled were 
of Eastern and Asiatic Population (with their genetic variability) 
and the treatment schedule used (UFT) was different from Euro-
pean and Western formulation. 
2.1.4. Methylenetetrahydrofolate Reductase (MTHFR) in CRC 
Patients Treated with 5-FU 
 Only few data are available about the role of others fluoro-
pyrimidines pathways correlated with 5-FU response. MTHFR is 
the enzymatic determinant of intracellular folate levels. A polymor-
phic region of the MTHFR gene termed 677T results in decreased 
enzymatic activity and subsequent increased levels of 5,10 methyl-
enetetrahydrofolate and is associated with a significantly improved 
response to 5-FU [21]. More recently, Fernández-Peralta AM et al. 
analyze the relationship of MTHFR C677T and A1298C polymor-
phisms with biological, clinicopathological, genetic and epigenetic 
features of tumors, and the patient outcome after treatment with 5-
FU-based chemotherapy. One hundred and forty-three Spanish spo-
radic CRC and 103 controls were analyzed by polymerase chain 
reaction/restriction fragment length polymorphism and sequencing. 
The C677T polymorphism has protective effect on CRC showing 
TT genotype with an odds ratio of 0.06 and a CT of 0.51, while 
MTHFR A1298C polymorphism is not associated with CRC risk. 
Patients with 1298CC and AC genotypes exhibit worse survival 
than those with the wild genotype (p = 0.001), whereas C677T 
genotypes do not affect patient survival (p = 0.92). MTHFR 677T 
allele carriers responded better to 5-FU-based chemotherapy than 
patients with the wild CC genotype (p = 0.05), and the variant C 
allele of A1298C affects negatively the response to 5-FU-based 
chemotherapy (p = 0.009) [22].  
 On these results, principally the variant allele of the C677T has 
a protective effect on CRC development, showing a possible role 
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for predictive response factor. Further studies also in this applica-
tion are necessary.  
2.2. Deoxyuridine Triphosphate Nucleotidohydrolase (dUT-
Pase). 
 dUTPase is a key regulator of intracellular dUTP pools and has 
been shown to be an important determinant of cytotoxicity medi-
ated by TS inhibitors by regulation of dUTP pools and prevention 
of detrimental uracil misincorporation into genomic DNA in the 
absence of thymine. Only a small retrospective study determined 
that elevated expression of dUTPase was associated with resistance 
to 5-FU, shorter time to progression, and reduced overall survival. 
In the last years this markers has been examined for its correlation 
with worse prognosis in CRC [23]. However, no other studies ex-
plain the exact role of this pathway in 5-FU therapy as predictive or 
prognostic factor. Kawahara A et al. analyzed 55 patients with co-
lorectal cancer, 20 without metastasis and the other 35 with distant 
metastasis with immunochemistry evaluation for dUTPase levels. 
The numbers of metastatic and non metastatic patients with expres-
sion of dUTPase (54% versus 15%, respectively; p=0.005) were 
significantly different in those with primary tumours with metasta-
sis compared with those with non-metastasis. It is suggested that 
dUTPase may be a predictive biomarker for the metastatic potential 
of colorectal cancer.[24]. Further evaluations must confirm these 
data. 
2.3. Microsatellite Instability: Background from the Literature 
 As previously described, microsatellite instability is the bio-
marker that could accurately predict tumour response in colorectal 
cancer treated with fluoropyrimidines. The majority of colorectal 
cancers display aneuploidy appearing as chromosomal anomalies, 
whereas the remainder that constitutes 15–20% of these cancers is 
characterized by microsatellite instability (MSI) [3, 25, 26]. Micro-
satellites are DNA sequences in which a short motif of 1–5 nucleo-
tides is tandem repeated ten to hundred times. Microsatellites are 
prone to mutation during replication due to transient split of the two 
helical strands and slippage of the DNA polymerase complex at 
reannealing, which generate an insertion or deletion loop depending 
on slippage direction. Unless such mismatch is corrected, the loss 
or gain of repeated units on the daughter strand results in length 
variation termed MSI [26]. To reduce this instability, the activity of 
mismatch repair (MMR) started and it is performed by the proteins 
hMSH2 heterodimerized with hMSH6. Upon assemblage, this 
complex interacts with another heterodimeric complex, composed 
of hMLH1 and hPMS2 [27]. Deficient MMR that arise in sporadic 
colorectal cancer is nearly always due to an epigenetic biallelic hy-
permethylation of the hMLH1 gene promoter, and from genetic 
disorders by an acquired alteration of the wild-type allele leading to 
inactivation of one of the three main MMR genes (MLH1, MSH2, 
and MSH6) [28].  
 MSI characterises a particular subset of colorectal cancers with 
specific characteristic biology and chemosensitivity. Several previ-
ous studies demonstrated in patients with local and advanced CRC 
that an high-frequency MSI (MSI-H) was associated with a favour-
able prognosis compared to microsatellite stable/low-frequency 
MSI (MSS/MSI-L), independently of chemotherapy [29, 30]. On 
the other hand, patients in treatment with 5-FU with MSS/MSI-L 
tumors had improved overall survival, whereas no similar benefit in 
outcome pertained to MSI-H tumors [30]. Initial investigations into 
the predictive role of microsatellite instability showed similar im-
provement in outcome from adjuvant 5-fluorouracil therapy irre-
spective of microsatellite status of the resected adenocarcinomas 
[31]. According all these data, there was an evidence of improved 
outcome from adjuvant 5-fluorouracil in terms of reduced recur-
rence rate and better OS related to patients with microsatellite sta-
ble tumors only [32, 33], whereas the subset having MSI cancers 
gained no similar beneficial effect from chemotherapy [29]. Ac-
cording these data, we can suggest that 5-fluorouracil therapy 
should not be given to patients with MSI colorectal cancer.  
 In a report of Watanabe T et al., the presence of a mutation in 
transforming growth factor-beta-RII (TGF-beta-RII) was shown to 
improve survival in patients who also possess MSI-H. The 5-year 
survival rate for patients with MSI-H tumors and the TGF-beta-RII 
mutation was 74% following adjuvant 5-FU-based therapy, com-
pared to 46% in patients with MSI-H tumors lacking the mutation 
in TGF-beta-RII. Interestingly, 61% of stage III colon cancers in 
this study exhibited the TGF-beta-RII mutation, indicating that this 
high frequency mutation may be useful in combination with MSI 
status as a prognostic marker for adjuvant therapy [34].  
 Jensen SA et al. measured the relationship between MSI and 
that biomarker. MSI in five reference loci, MMR enzymes 
(hMSH2, hMSH6, hMLH1 and hPMS2), TS and DPD expression 
were assessed in paraffin embedded tumor specimens, and associ-
ated with outcome in 340 patients completely resected for colorec-
tal cancer stages II-IV and subsequently receiving adjuvant 5- 
fluorouracil therapy [35]. Microsatellite status was assessed in 311 
(92%) of 340 tumors and MSI tumors with instability in at least 
three and in most cases four markers were found. MSI was found in 
43 (13.8%) tumors and MSI tumors were prevalently in more eld-
erly patients, (P = 0.02), in poorly differentiated tumor types (P = 
0.001), in tumor mainly located proximally to the splenic flexure in 
ascending and transverse colon (P = 0.001). No statistically signifi-
cant differences (P > 0.05) were found according to microsatellite 
status regarding gender, stage, vascular tumor invasion, perineural 
tumor invasion, or tumors complicated by perforation. In multivari-
ate analysis, MMR deficient compared to MMR proficient tumors 
were significantly associated with lower risk of recurrence (HR = 
0.4; P = 0.003) and death (HR = 0.5; P = 0.02), while MSI com-
pared to MSS tumor patients had significantly lower risk of recur-
rence (HR = 0.3; P = 0.0007) and death (HR = 0.4; P = 0.02) [35]. 
The distribution of biomarkers according to microsatellite status in 
the study indicated a direct relationship between MSI/MMR and 
increasing TS staining intensity (P = 0.001), recurrence (P = 0.002) 
and overall survival (P = 0.02), while there was no evidence of an 
association with DPD in all these variables (P = 0.1) [35].  
 On these premises, the outcome according to microsatellite 
status in the present study can therefore be ascribed mainly to the 
biology of MSI colorectal cancer and to a lesser extent to antitumor 
response to 5-fluorouracil therapy. The correlation between high TS 
expression and microsatellite instability should be interpreted cau-
tiously. There are no evidence to suggest direct influence of micro-
satellite instability on DPD or TS expression, nor that differential 
expression of these enzymes mediates the features for tumor biol-
ogy or 5-FU resistance of MSI carcinomas. The reason of this asso-
ciation failure is due to technical reasons: the most significant limi-
tation of immunohistochemistry is the semiquantitative nature of 
immunostaining. For these reasons, Microsatellite instability due to 
MMR deficiency remain one of the main biomarkers in colorectal 
cancer, as it not only indicates the pathogenesis, but also provides 
information on prognosis and prediction of response to chemother-
apy. Future investigations into gene targets for microsatellite insta-
bility-driven deregulation are necessary to clarify the exact molecu-
lar foundation for the distinct clinico-pathological characteristics of 
MSI tumors. 
2.4. Loss of Heterozygosity of 18q and 17p 
 It is reported in literature that allelic deletions involving chro-
mosomes 18q and 17p occur in more than 70% of CRC [36]. Such 
deletions are thought to signal the existence of a tumor suppressor 
gene in the affected region. The tumor suppressor gene p53, often 
referred to as the “guardian of the genome” due to its central role in 
detection of genotoxic stress, is located on 17p and is mutated in 
40% to 60% of colorectal cancers [36]. The p53 status has been rig-
orously analyzed as both a prognostic and predictive marker in 
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CRC, with conflicting results. Retention of 18q alleles in MSS can-
cers points to a favourable outcome after adjuvant chemotherapy 
with 5-FU–based regimens for stage III colon cancer [37]. The 18q 
chromosome contains DCC (deleted in colon cancer), a cell adhe-
sion molecule, whose elevated expression can lead to enhanced tu-
mor growth and metastatic potential. Several studies have deter-
mined that cancers with chromosome 18q loss appear to be associ-
ated with worse disease-free and overall survival [29, 37]. Further 
studies are necessary to determine the prognostic value of these ge-
netic molecular markers. 
2.5. Oral Fluoropyrimidines: Pharmacology and Predictive 
Markers 
 Even if 5-FU remains one of the most commonly prescribed 
anticancer drugs with significant activity against CRC, repeated and 
protracted intravenous administrations are heavy for patients. In the 
last years new oral 5-FU prodrugs, with new pharmacological char-
acteristics, are emerging in the clinical area for the treatment in on-
cology [38]. New 5-FU prodrugs differ markedly in their mode of 
activation, their pharmacokinetic behaviour, particularly related to 
DPD inhibition, and their pharmacologic modulation. The 5-FU 
prodrugs currently at more or less advanced stage of clinical devel-
opment are Eniluracil (5-Ethynyluracil), UFT (Uracil + tegafur), S-
1 (5-Chloro-2, 4 dihydropyrimidine + tegafur + potassium oxonate) 
and the most used Capecitabine (N4-pentyloxycarbonyl-5’-deoxy-
5-fluorocytidine) [39] (Table 1). Their activity is related to the 
pharmacologic benefits conferred by the inhibition of 5-FU catabo-
lism during gastrointestinal absorption and first pass in the liver, by 
DPD inhibition. DPD inhibition improves pharmacokinetic behav-
iour of delivered 5-FU by reducing interpatient variability and by 
increasing 5-FU half-life, particularly useful in limiting repeated 
oral administrations of the drug which is uncomfortable for pa-
tients. At one extreme, eniluracil has no cytotoxic activity but con-
stitutes the most efficacious DPD inhibitor, through the formation 
of a covalent bond with DPD. UFT, including uracil (U), is a simple 
competitive inhibitor of DPD activity since it is the natural sub-
strate of DPD. S-1 incorporates another DPD competitor, 5-chloro-
2,4-dihydroxypyridine which is 200-fold more potent than U [39]. 
At the other extreme, Capecitabine does not incorporate a DPD in-
hibitor and is converted to the cytotoxic moiety 5-FU in target tis-
sue through a series of three metabolic steps [40].  
 Oral fluoropyrimidines differ particularly as concerns their 
pharmacokinetic profile. Eniluracil was initially administered with 
5-FU in a 10 : 1 ratio and produces 5-FU directly in the blood com-
partment. Baker et al. reported the pharmacokinetic of enluracil, 
with elimination half-life of 5-FU around 4.0 hours and constant 
pharmacokinetic parameters between day 2 and day 29 [41]. The 
promising results of this DPD inactivator disappeared due to its 
high toxicity, as explained in subsequently clinical studies. Hirata et 
al first reported the pharmacokinetics of 5-FU following the ad-
ministration of S-1 at a standard dose of 80 mg/m
2
 on day 1, with 
evidence of relative stability in the pharmacokinetics of 5-FU dur-
ing S-1 treatment. Elimination half-life of 5-FU during S-1 treat-
ment was in the range of 1.9–2.9 hours [42]. Also the pharmacoki-
netic of UTF explain the stability of levels of 5-FU in plasma. A 
steady state was attained for UTF and 5-FU at least on day 8 and 
there was no further cumulative increase in the AUC of these com-
pounds after 1 week of treatment [43]. In colorectal patients treated 
by UFT, Sadahiro et al (2001) examined the respective concentra-
tions of 5-FU in serum, tumour and normal mucosa at various in-
tervals after the final dose of UFT. While the serum 5-FU concen-
tration decreased to very low levels by 24 h following the UFT 
dose, the intratumour concentration of 5-FU had been lowered to 
only about half, and drug levels in normal mucosa were maintained 
at least 48 h after the final dose [44].  
 The clinical pharmacokinetics of capecitabine has been initially 
studied by Reigner et al . The preferential delivery of 5-FU into the 
tissues through the intermediary of thymidine phosphorylase (TP) is 
responsible for its much lower presence (approximately 10 times 
lower) in plasma than its prodrugs capecitabine, 50DFCR, 50DFUR 
or its catabolites FUH2 and FBAL. The authors noted that the AUC 
of capecitabine, 50-DFCR and 50-DFUR did not increase in plasma 
after long-term administration [45]. The influence of various co-
variables including gender, biological functions, food intake and 
coadministration of other drugs has been examined for the pharma-
cokinetics of oral fluoropyrimidines. In particular, pharmacokinetic 
changes due to food have been particularly well studied for UFT 
and capecitabine, with evidence that food had marked effects on the 
AUC of capecitabine, as 50% reduction. Consequently, it was rec-
ommended that capecitabine be administered with food [45]. In 
contrast, Damle et al. demonstrated that food significantly de-
creased the maximal plasma concentrations and UFT AUC values. 
These observations led to the conclusion not to administer UFT si-
multaneously with food [46]. In patients with renal dysfunction and 
hepatic dysfunction, treated by capecitabine there was a significant 
increase in 50DFUR. This led to specifically recommend a dose 
modification of capecitabine for patients with very low creatinine 
clearance and increase levels of liver failure markers [47].  
Table 1. Oral Fluoropyrimidines Under Clinical Evaluation 
Compound Chemical Name 5-FU Prodrug Effect on DPD 
Eniluracil  
(Clinical development stopped) 
5-Ethynyluracil No Inactivator (complete 
DPD inhibition) 
UFT  
(Orzels® , Bristol-Myers Squibb, contains UFT plus 
leucovorin) 
Uracil + tegafur Yes Inhibitor 
S-1  
(Bristol-Myers Squibb) 
5-Chloro-2, 4 
Dihydropyrimidine + tegafur + potassium oxonate 
Yes Inhibitor 
Capecitabine  
(Xeloda®, Roche) 
N4-pentyloxycarbonyl-5’-deoxy-5-fluorocytidine Yes No DPD inhibitor 
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 Whatever the oral fluoropyrimidine considered all release 5-FU 
which is the final cytotoxic prodrug. Consequently, our clinical 
knowledge of the predictive markers for 5-FU-based treatment effi-
cacy should apply to oral fluoropyrimidines. Ichikawa et al. [19] 
examined the relative tumoural expression of DPD and TS for ad-
vanced colorectal patients to be treated by UFT, as previously de-
scribed. Capecitabine ultimately delivers 5-FU at the cellular level 
through the action of TP; for this reason, the flux of 5-FU produc-
tion can be counterbalanced by a more or less marked opposite flux 
of 5-FU intracellular catabolism mediated by DPD. This view was 
confirmed by Tsukamoto et al (2001), who measured, in vitro, the 
enzyme kinetic parameters of each of the enzymes involved in the 
activation of capecitabine to 5-FU and elimination [48]. The 
authors constructed a physiologically based pharmacokinetic model 
which revealed that the most important factors determining the se-
lective production of 5-FU in tumour tissue after capecitabine ad-
ministration were activation by TP, nonlinear elimination of 5-FU 
by DPD and the tumour blood flow rate. These data confirmed 
those previously reported by Ishikawa et al. [20] showing the effi-
cacy of capecitabine correlated to the tumour TP/DPD ratio. 
 Overall, our current understanding of predictive markers for 
oral fluoropyrimidine treatment is limited and, with the exception 
of UFT, remains based on extrapolations from 5-FU clinical stud-
ies. Further studies are necessary in the future, in consideration of 
the widely use especially of capecitabine in adjuvant and first line 
treatment of CRC. 
2.6. Fluoropyrimidines and Markers of Toxicity 
 Although the fluoropyrimidines (5-FU and derivates) are in 
clinical use for almost 50 years, there is still no clear methodology 
to identify patients who are likely to benefit most from the treat-
ment. Therefore, there is a clear need to identify several markers to 
predict the treatment toxicity and provide a rational basis for treat-
ment selection. 
 Numerous serious adverse side effects have been reported with 
fluoropyrimidine treatment, including myelosuppression, cardiac 
toxicity, mucositis, hand-foot syndrome (HFS), and diarrhoea [49, 
50]. The oral derivate capecitabine in the last years has been fa-
voured because of the convenience of its administration. In addi-
tion, capecitabine is better tolerated by patients, who reported fewer 
cases of stomatitis, alopecia, neutropenia, diarrhoea, and nausea, 
but more cases of HFS, compared to 5-FU [51]. These toxicities can 
have significant effects on treatment time and cost, including dose 
reductions, treatment delays, changes in or discontinuation of ther-
apy, extra interventions to address potentially harmful side effects, 
fluid- and nutritional-replacement therapies, hematopoietic-stimu-
lating therapies, use of antibiotics, hospitalization, and poor quality 
of life. 
2.6.1. Dihydropyrimidine Dehydrogenase (DPD)  
 In contrast with the not well defined 5-FU and derivates 
mechanism of activation, the 5-FU elimination pattern is univocal. 
Catabolism and deactivation of fluoropyrimidine drugs depend on a 
single and exclusive enzymatic step driven by dihydropyrimidine 
dehydrogenase (DPD). With the increasing number of patients with 
cancer likely to be treated with fluoropyrimidines, predicting and 
preventing the occurrence of such toxicities is now a major issue in 
clinical oncology [51]. The drug displays an extensive first-pass 
metabolism, because > 95% of an administered dose of 5-FU is 
quickly dehydrogenated in the liver by DPD to dihydrofluorouracil 
(5-FU-H2). Dihydrofluorouracil is subsequently converted to beta-
fluoro-beta-ureido-propionic acid, then fluoro-beta-alanine (Fbe-
taAL) by dihydropyrimidinase and beta-ureidopropionase, respec-
tively, and conjugated FbetaAL derivatives are eventually elimi-
nated in urine [52]. DPD is the initial and rate-limiting enzyme in 
the pathway. For the past 20 years, a causative link between defi-
ciency in DPD activity and severe toxicity in response to 5-FU and 
derivates treatment, including grade 4 symptoms and death, has 
been extensively studied. It has been shown that DPD activity was 
slightly lower in women (< 15%) than in men [39]. The pivotal role 
of DPD in 5-FU-based chemotherapy has been shown in CRC pa-
tients with a complete or partial deficiency of this enzyme. These 
patients suffered from severe, possibly fatal multi-organ toxicity 
following the administration of 5-FU [39, 53, 54]. 
 DPYD, the gene encoding DPD, located within human chromo-
somal region 1p22, is composed of 23 exons encompassing ap-
proximately 950 kb [55, 56]. Over 30 single nucleotide polymor-
phisms (SNPs) and deletion mutations have been identified within 
DPYD, although most of these variants have no functional conse-
quences on enzymatic activity. Of particular interest is the IVS14 + 
1 G > A variant (DPYD*2A), which has been found in up to 40–
50% of people with partial or complete DPD deficiency [57].  
 Aberrant methylation of the DPYD promoter was found to 
cause a partially DPD deficient phenotype [58-60]. Meta-analysis 
of over 1200 patients suggested that more than 30% of patients 
treated with 5-FU experienced severe drug-related toxicity [61]. 
The frequency of low DPD enzymatic activity, indicating partial 
DPD deficiency, in the general population was initially estimated at 
between 3% and 5% [62]. Additional studies have shown signifi-
cant variability among different ethnic subpopulations, showing 
that the prevalence of partial DPD deficiency is higher in Asian 
[63], Southwest Asian [64], African [65], American [66] than 
European and Caucasian Group [67, 68]. 
 Several possible methods are used for testing DPD levels. The 
most common test, used as control system in several comparative 
tests, involves the ex vivo incubation of a patient’s peripheral blood 
mononuclear cells (PBMCs) with radiolabelled 5-FU and measur-
ing the resulting rate of catabolite formation by high-performance 
liquid chromatography (HPLC) [69]. An alternative method of 
measuring DPD enzymatic activity is the Real-time quantitative 
PCR of DPD [70]. A recent report, using a small number of pa-
tients, suggested measuring plasma levels of fluoro--alanine 
(FBAL), the final metabolite of 5-FU in the catabolic pathway, by 
HPLC to assess DPD enzyme activity [70]. More promising alter-
nate assays involve measuring uracil levels to determine DPD activ-
ity, prior to starting on a 5-FU or capecitabine therapeutic regimen. 
Several recent studies found that elevated levels of uracil in plasma 
were significantly associated with impaired clearance of 5-FU and 
development of 5-FU-related toxicity [70]. A new test for uracil 
catabolism was developed. Forty-two subjects ingested an aqueous 
solution of 2-13C-uracil, and exhaled levels of 13CO2 and 12CO2 
were measured using infrared spectrophotometry [71]. At last, sev-
eral groups have reported tests, using the WAVETM DNA Frag-
ment Analysis System, developed by Transgenomic, connected to a 
denaturing HPLC (DHPLC) for the detection of DNA mutations in 
DPYD [72].  
 Many reports have studied the correlation between specific 
DPYD mutations and DPD activity. In particular, the studies of 
Largillier explore the development of grade 3 or 4 adverse side ef-
fects correlated with DPYD gene mutations [73] and concluded that 
genetic mutation in DPYD does not always translate into severe 5-
FU toxicity.  
 On this basis, subsequently, various strategies have been pro-
posed to screen for patients with a DPD deficiency, including geno-
typing [74, 75]. The evidence that DPYD heliotype not containing 
any no synonymous or splice-site mutations was associated with 5-
FU toxicity suggested the presence of additional genetic variations 
in the nonbonding region of DPYD [74]. No deep intrinsic muta-
tions in DPYD have been described affecting the splicing of DPD 
pre-mRNA, as evidenced in 7% of paediatric patients with a com-
plete DPD deficiency [76]. Therefore, it is conceivable that ge-
nomic deletions encompassing a part or the entire DPYD gene 
might also provide a molecular basis for cancer patients with a phe-
notypic ally established DPD deficiency. For this reason, van Duis-
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enberg et al. [77] recently investigated the presence or absence of 
genomic rearrangements in DPYD, using multiplex ligation-
dependent probe amplification (MLPA), in 92 patients with a re-
duced DPD activity and/or grade III/IV toxicity. This German study 
characterized a novel missense mutation K874R based on the crys-
tal structure of DPD and identified the first deep intronic mutation 
in DPYD affecting the regulation of pre-mRNA splicing. Analysis 
of the prevalence of the various DPYD mutations, in cancer patients 
experiencing severe toxicity, showed that the splice-site mutation 
c.1905 + 1G/A (IVS14 + 1G/A) and the c.2846A/T (D949V) were 
the most common pathological mutations, data confirmed also in 
the study of Loganayagam et al. [78]. The deleted region, encom-
passing exons 21–23, was located outside the common fragile site 
FRA1E which extends over 370 kb within DPYD [79]. In a sub-
groups analysis, conspicuous finding was a deep intronic mutation 
affecting DPD pre-mRNA splicing in five individuals. The c.1129–
5923C/G mutation in intron 10 created a cryptic splice donor site 
and as a consequence, a 44 bp fragment of intron 10 was inserted in 
the mature DPD mRNA, reducing its activity. Really, conflicting 
data exist as to weather the c.1236G/A mutation is associated with 
an increased risk of development of severe 5-FU-associated toxicity 
[75, 80], because of its apparently high mutation prevalence in the 
normal population. These data refer the necessity to confirm the 
genetic screening for this mutation in cancer patients prior to the 
start of 5-FU-containing chemotherapy 
 In another study, Amstutz et al. [81] analized the hypermethyla-
tion of the DPYD promoter region as an alternative mechanism for 
DPD deficiency and severe 5-FU toxicity. The ipermethylation was 
assessed in 27 cancer patients (22 gastrointestinal cancer patients), 
receiving 5-FU based chemotherapy, including 17 patients experi-
encing severe toxic side effects following drug administration. 
None of which were carriers of a known deleterious DPYD muta-
tion, and ten control patients. The final results showed no evidence 
of DPYD promoter methylation, whereas in a control experiment, 
as little as 10% methylated genomic DNA could be detected.  
 Various studies nevertheless suggest epigenetic factors as an 
alternative explanation for the occurrence of severe 5-FU toxicity 
where no other molecular basis was found in DPYD [82, 83]. 
Probably because only of minor importance as a predictive factor 
for severe toxic side effects in 5-FU based chemotherapy 
2.6.2. Tymidilate Sinthetase (TYMS) and Methylene Tetrahydro-
folate Reductase (MTHFR)  
 Various polymorphisms in genes other than DPYD have re-
cently been shown to be correlated with the occurrence of severe 
adverse side effects to 5-FU.  
 Previous results on tymidilate sinthetase (TYMS) and methyl-
ene tetrahydrofolate reductase (MTHFR) polymorphism showed by 
Pullakart et al. [14] were tested in subsequent studies, in particular 
by Schwab et al. The authors evaluated the TYMS gene, with his 
variations in certain regions, which alter its expression and relative 
enzyme, a target of 5-FU-based therapy. Low levels of enzyme 
(2R/2R) are associated with a 1.4 - 2.5-fold risk of toxicity to 5-FU-
based therapy, in particular diarrhea [80].  
2.6.3. Orotate Phosphoribosyltransferase (OPRT) 
 Although the importance of the value of TYMS and DPD in the 
cytotoxicity of 5-FU is recognized, the contribution of phosphoryla-
tion is necessary to activate 5-FU into its nucleotides [19]. The 
preferential use of the pathway directly to FUMP by orotate phos-
phoribosyltransferase (OPRT) was revealed to correlate with the 
cytotoxicity of 5-FU [83]. FUMP is then phosphorylated to fluoro-
uridine diphosphate, which can be either converted to FdUMP or 
phosphorylated to the active metabolite fluorouridine triphosphate. 
Fluorouridine triphosphate is extensively incorporated into RNA 
(F-RNA), disrupting normal RNA processing and function [83].  
 Using this concept, Ichikawa et al. enrolled 69 patients with 
CRC B2-C Dukes from January 2000 to August 2002, who under-
went radical surgery and received bolus 5-FU. All eligible patients 
were treated between 14 and 35 days after surgery with the Roswell 
Park regimen (500 mg/m
2
 5-FU i.v. bolus given 1 hour after L-
leucovorin infusion weekly for 6 weeks, combined with 250 mg/m2 
L-leucovorin by 2-hour infusion; four treatment cycles were given, 
each consisting of six weekly treatments followed by a 2-week rest 
period). OPRT Gly213Ala polymorphism was successfully assessed 
for all 69 patients, utilizing samples genotyped for OPRT 
Gly213Ala polymorphism by Assay-by-Design by Applied Biosys-
tems (ABI, Foster City, CA) [83], and finally verifying analysis of 
OPRT activity and mRNA expression. The authors concluded that 
there was no statistical association of OPRT Gly213Ala promoter 
polymorphisms with the clinicopathologic features, such as age, 
gender, performance status, location of primary tumor (colon, rec-
tum), tumor depth of invasion, and Dukes’ classification.  
 The OPRT Gly213Ala promoter polymorphisms were demon-
strated factors to predict grade 3 to 4 diarrhea. The frequency of the 
Ala allele of OPRT Gly213Ala polymorphism was 27.5%. The Ala 
allele was also associated with increased OPRT mRNA level in 
normal tissue, leading to the hypothesis that this polymorphism 
could play a role in mRNA stability and translation. Patients with 
the Ala allele were 16 times more likely to have severe toxicity 
compared with those normal (Gly/Gly genotype) [83].  
 Moreover, a conspicuous finding was that the onset of severe 
toxicity occurred earlier from the start of chemotherapy in patients 
with the Ala/Ala genotype than those with other genotypes. For this 
case, OPRT Gly213Ala polymorphism might predict not only the 
risk of toxicity but also the time of the occurrence of severe toxic-
ity. Prospective translational treatment trials, including larger num-
ber of patients, are needed to corroborate these results and resolve 
these questions. 
2.7. 5-Fluorouracil Test Dose 
 Reduced test dose strategies with subsequent sampling for 
pharmacokinetic evaluation could provide valuable information on 
patients with impaired DPD and increased risk of iatrogeny upon 5-
FU administration. Monitoring of 5-FU and 5-FU catabolites such 
as dihydrofluorouracil [84] in plasma has been proposed as a 
marker for DPD function. A recently demonstrated pharmacoki-
netic-based test to prevent severe toxicities upon 5-FU administra-
tion showed that using a reduced 5-FU test dose with 5-FU/5-FU-
H2 monitoring permitted one to detect approximately 2% of pa-
tients with marked alterations in 5-FU pharmacokinetic profiles. 
These patients were subsequently selected for alternative treatments 
without fluoropyrimidine drugs, thus preventing life-threatening 
toxicities [80]. 
 On this basis, a recent Test (Thera Guide, Myriad Genetic 
Laboratories, Inc. of Salt Lake City, Utah, USA) was performed to 
provide comprehensive analysis of the DPYD and TYMS genes to 
identify high-risk individuals and help prevent toxicity in patients 
being considered for 5-FU-based therapy. The classification is de-
fined in three class of risk (high: together mutated, moderate: only 
TYMS mutated, low: no mutations) to whom is based the final de-
cision to include in therapy 5-FU and derivates. 
 In conclusion, choosing a method for identifying DPD-deficient 
patients at risk with fluoropyrimidine drugs remains an uneasy task. 
No method has stood out as a standard that would meet all the re-
quirements (e.g., time- and cost-effectiveness, availability, and 
relevance) of large-scale screening. We can explain that, in the ab-
sence of new better alternative chemotherapies, screening patients 
for conditions that would predispose them to being unable to toler-
ate 5-FU, such as DPD deficiency, remains the best solution for 
improving patient outcomes and the techniques for assessing DPD 
deficiency, more than OPRT polymorphism, must be finally refined 
and should include a search for genomic rearrangements and aber-
rant splicing to permit that screening will become practicable in the 
future. 
Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines Current Drug Metabolism, 2011, Vol. 12, No. 10    925 
3. OXALIPLATIN 
 After the previously described 5-FU efficacy as therapeutic op-
tions in the treatment of advanced CRC (RR 20-25%), the introduc-
tion of newer agents, such as oxaliplatin in combination with 5-FU, 
has increased response rates to 40% to 50% in advanced disease 
and improved overall survival [85, 86]. Selection of the most bene-
ficial treatment regimens in CRC remains a challenge and is hin-
dered by a lack of predictive and prognostic markers. In addition, 
drug resistance remains a major stumbling block to effective cancer 
treatment. 
 Oxaliplatin is a third-generation platinum analogue in which the 
1,2-diaminocyclohexane (DACH) ligand substitutes the amine 
groups of cisplatin. Oxaliplatin also exhibits a relatively favourable 
toxicity profile and in many instances is clinically more favourable 
than cisplatin, with reduced toxicity and substantial activity against 
cisplatin- resistant tumors platinum compounds form positively 
charged species that cause DNA-damaging crosslinks blocking both 
DNA replication and transcription and initiating apoptosis [87]. 
 Several distinct mechanisms are proposed to mediate response 
to oxaliplatin, including increased drug inactivation and efflux, de-
creased cellular uptake/accumulation, enhanced tolerance to pt-
DNA damage, and an increase in the efficiency of DNA repair 
mechanisms [88].  
3.1. Nucleotide Excision Repair (NER) Pathway: ERCC1  
 The nucleotide excision repair (NER) pathway represents the 
resistance mechanism best described to date for removal of the 
bulky pt-DNA adducts induced by oxaliplatin treatment (see 
above). The more studied and conserved member of the NER path-
way implicated in mediating response to oxaliplatin is excision re-
pair cross-complementation group 1 (ERCC1). ERCC1 forms a 
complex with xeroderma pigmentosum group F (XPF), which rec-
ognizes and cleaves the 5 damaged DNA strand in lesion repair 
[88] (Fig. 2). 
 Several studies in the last 20 years have correlated ERCC1 gene 
expression levels with clinical outcome in patients receiving a 
platinum-based regimen, from data related to ovarian carcinoma 
[89] to analyses in CRC patients [90, 91]. Shirota Y et al. analyzed 
ERCC1 mRNA expression level in a study of 50 patients with ad-
vanced disease refractory to 5-FU/irinotecan chemotherapy, and it 
results to be an independent predictive marker of survival in 5-
FU/oxaliplatin chemotherapy (P < .001) [90]. The influence of po-
lymorphisms in ERCC1 and XPD genes on outcomes in patients 
with metastatic CRC (mCRC) receiving first-line therapy with 5-
FU/LV/oxaliplatin (FOLFOX4) was examined using peripheral 
blood samples from 166 patients. Genotypes independently associ-
ated with shorter progression-free survival (PFS) included ERCC1-
118 T/T, XPD-751 A/C, and XPD-751 C/C. The median PFS was 
11.2 months for patients without any of the 3 genotypes, 9.8 months 
for those with 1 of the high-risk genotypes, and 8 months for those 
with both the ERCC1-118 T/T and either XPD-751 A/C or C/C 
genotypes (hazard ratio, 2.84; P= .002) [92]. 
 The ERCC1-118 T allele has been associated with higher 
ERCC1 mRNA levels, which supports the profile of oxaliplatin re-
sistance. Polymorphic variants within the ERCC1 gene have been 
identified and associated with clinical outcome in patients receiving 
5-FU/oxaliplatin [91]. Partly different from fluoropyrimidines 
genes previously described, the frequency of these polymorphisms 
varies with race and may account for reduced response rates in 
black patients when compared with white patients, as expressed by 
Goldberg RM et al. and confirmed in more recent studies, as in the 
subgroup of patients of CAIRO study [93, 94].  
 Subsequently, recent studies investigated the ERCC1 role alone 
and together with other factors. Kim SH et al. evaluated whether 
the expression of ERCC1, together with TS and glutathione S-
transferase pi (GSTpi), examined using immunochemistry, predict 
clinical outcome in 70 patients with advanced colorectal cancer 
treated with 5-FU/oxaliplatin chemotherapy. The results showed 
that ERCC1, TS, and GSTpi were positive in 55.7%, 68.6%, and 
71.4% of cases, respectively. While it was confirmed that TS lower 
levels correlate with best response to chemotherapy (P = 0.009), 
there was no significant correlation between response to treatment 
and the ERCC1 or GSTpi expression pattern (P = 0.768, P = 0.589, 
respectively). The median OS, however, was significantly longer in 
patients without ERCC1 expression (P = 0.0474). Patients who 
were simultaneously ERCC1 and TS positive had a poor OS (P = 
0.0017). Multivariate analysis revealed and confirmed that both 
ERCC1 and TS expression significantly impacted OS (HR 1.72, P = 
0.023), justifying the dosage of these factor for the prediction of 
clinical outcome in this patients group [95]. 
3.2. Nucleotide Excision Repair (NER) Pathway: XRCC1 
 Another member of the NER pathway is X-ray cross-comple-
menting group 1 (XRCC1) and together with ERCC1 was analyzed 
in the study of Liang J et al [96]. The authors evaluated the effect of 
the two gene polymorphism, ERCC1 codon 118C/T and XRCC1 
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codon 399A/G, tested by RT-PCR method in peripheral blood lym-
phocytes, on treatment outcome in 113 patients with a diagnosis of 
metastatic colorectal cancer receiving oxaliplatin-based regimens. 
Analyses of the patterns of the polymorphism located at ERCC1 
codon 118 showed that 55 (48.67%) patients were homozygous for 
C/C genotype, 15 (13.27%) were homozygous for the T/T geno-
type, and 43 (38.06%) were heterozygous for C/T genotype. Analy-
ses of the polymorphism located at XRCC1 codon 399 showed that 
61 (53.98%) patients were homozygous for A/A genotype, 13 
(11.50%) were homozygous for the G/G genotype, and 39 (34.52%) 
were heterozygous for A/G genotype. Adjusted for some clinical 
factors, ERCC1 and XRCC1 polymorphisms alone lost their roles 
in predicting disease control rates (DCR) and OS (P = 0.662 and 
0.631, respectively), while the combination of two genes polymor-
phisms was significantly associated with DCR (P = 0.01) and OS (P 
= 0.001), independently, becoming the first study to demonstrate a 
possible selection of patients who would benefit from oxaliplatin-
based chemotherapy for metastatic colorectal cancer [96]. 
3.3. Nucleotide Excision Repair (NER) Pathway: XDP 
 Interestingly, xeroderma pigmentosum group D (XPD) is an-
other gene that codes for an important protein in the NER pathway. 
A polymorphic variant at position 751 results in a lysine to glu-
tamine substitution and has been linked with significantly lower 
response rates in a study of 73 patients receiving 5-FU/oxaliplatin. 
Patients with the Lys/Lys genotype demonstrated a median survival 
of 17.4 months whereas those possessing the Lys/Gln and Lys/Gln 
demonstrated 12.8 and 3.3 months respectively (P = 0.02) [97]. X-
ray repair cross complementing 1 (XRCC1) is involved in the repair 
of single strand breaks following base excision repair and has been 
demonstrated to mediate repair of alkylating agent-induced DNA 
damage [98]. A study by Stoehlmacher et al analyzed gene expres-
sion of the XRCC1 polymorphic variant found at codon 399 in a 
61-patient study [99]. Seventy-three percent of patients with the 
favourable Arg/Arg genotype responded to treatment, and patients 
who possessed at least one Gln allelic polymorphism in XRCC1 
were 5.2-fold more likely to fail 5-FU/oxaliplatin chemotherapy.  
 This polymorphic was also identified as demonstrating signifi-
cant heterogeneity according to race-again a possible determinant 
of race-specific response [93] . One study demonstrated the poten-
tial benefits of performing multivariate analysis of multiple gene 
polymorphisms in patients with refractory colorectal cancer and 
identified a gene dosage effect on 5-FU/oxaliplatin treatment re-
sponse with patients with two or more unfavourable XPD, TS, 
ERCC1, and GST-P1 polymorphisms having a significantly re-
duced OS [100] . 
3.4. DNA Repair Pathways 
 The precise clinical effect of modulation of components of the 
DNA repair pathways in platinum drug efficacy remains to be 
clearly established. The majority of oxaliplatin that enters cells 
never becomes associated with DNA. A possible explanation for 
this is inactivation via formation of conjugates between glutathione, 
detoxification by the glutathione-S-transferase (GST) family, and 
exportation of the complexes via the ABC membrane transporter 
superfamily [101, 102]. Studies have identified polymorphisms in 
GST enzymes that have been correlated with response to platinum 
agents. One polymorphic variant results in an amino acid substitu-
tion at position 105 of GSTP1, which is reported to diminish enzy-
matic activity. A study of 107 patients determined that those homo-
zygous for the val/val genotype demonstrated significantly longer 
survival compared with those heterozygous or homozygous for the 
wild type [103] and an additional study linked the GST-P1 105V 
polymorphism to drug activity, efficacy and sensory neurotoxicity 
in patients receiving FOLFOX, this last aspect subsequently de-
scribed [104]. 
 
3.5. Oxaliplatin Toxicity 
 Oxaliplatin frequently causes neutropenia, fatigue, gastrointes-
tinal symptoms (nausea, vomiting, and diarrhea), ototoxicity (hear-
ing loss), and saltuary hypokalemia. However, the primary toxicity, 
dose limited in many cases, is a purely sensory neuropathy, which 
seems to be cumulative and, at least in a large part, reversible with 
drug cessation. CRC patients treated with oxaliplatin discontinue 
therapy more often because of peripheral neuropathy than tumor 
progression, potentially compromising patient benefit. The Food 
and Drug Administration noted that more than 70% of the patients 
receiving oxaliplatin are affected by some degree of sensory neu-
ropathy [105]. Most importantly, neurotoxicity, and not tumor pro-
gression, is often the cause of treatment discontinuation. An addi-
tional recent study examining 383 patients treated with oxaliplatin 
and irinotecan showed that 52% of patients required dose reduction 
due to adverse events, including neurotoxicity, and that 26% re-
quired hospitalization because of these negative events [106]. There 
are two patterns of neuropathy: an acute cold-aggravated but tran-
sient condition and a more chronic form that has onset after multi-
ple exposures to the drug and that often improves but does not dis-
appear with drug cessation. Acute oxaliplatin neurotoxicity can oc-
cur within hours of dosing as this may be precipitated or exacer-
bated by exposure to cold temperature or cold objects and typically 
resolves within hours to days [107]. This acute neurotoxicity is dose 
related and reversible. The more chronic pattern of sensory neu-
ropathy was observed in 50% of study patients who received ox-
aliplatin with infusional 5-fluorouracil/leucovorin [108]. Ox-
aliplatin, less than cisplatin but more than carboplatin, undergoes 
aquation, which is a key step in the drug forming a complex with 
the target DNA. The result of this hydrolysis is the formation of a 
positively charged molecule that then cross-links to DNA, forming 
the DNA/platinum adducts. The amount of DNA crosslinks in DRG 
neurons at a given cumulative dose was significantly correlated 
with the degree of neurotoxicity [109].  
 Although the mechanism of the transition from a platinum-
DNA adduct to neuronal apoptosis is not fully understood, one pro-
posal has suggested that the DNA repair machinery is unable to re-
pair the damaged DNA. Polymorphisms in the DNA repair genes, 
including genes in base excision repair, nucleotide excision repair, 
mismatch repair, and double-strand break repair pathways, cause 
the individuals to be less proficient in repairing carcinogen-induced 
damage. It has also been proposed that the platinum-DNA adducts 
interfere with the normal function of cellular proteins such as bind-
ing or interactions with other proteins [110]. 
 In addition to efforts to identify a successful neuroprotective 
agent, there have been numerous studies attempting to establish the 
role of various phenotypic markers for chemotherapy-induced neu-
rotoxicity. An accurate marker of neurotoxicity that would enable a 
quantitative monitoring of progress of neurotoxicity or provide a 
prediction of the ultimate severity would prove valuable in control-
ling this toxicity. Cavaletti et al. proved initially a highly significant 
correlation between the decrease in circulating levels of nerve 
growth factor and the severity of chemotherapy-induced neurotox-
icity in patients treated with platinum drugs and taxanes, however, 
it did not predict the final neurologic outcome and further studies 
are request to provide an effective benefit for this class of patients 
[111]. Subsequently, many efforts have been made to determine 
genetic linkages as a cause of platinum-based toxicity in order to 
ultimately diminish these effects and augment the beneficial anti-
tumor qualities. A great number of genome-wide studies have been 
pursued.  
3.5.1. Glutathione S-transferase (GST) 
 The more important data were directed to Glutathione S-
transferase (GST) enzymes, which are responsible, in part, for ox-
aliplatin detoxification. Glutathione S-transferases (GST) are a  
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family of enzymes that catalyze the conjugation of glutathione to 
electrophilic toxins to inactivate them and aid in their excretion 
from the body [92]. The GST genes encode metabolizing enzymes 
that decrease the reactivity of toxins with substrates in the body. 
Genetic polymorphisms have been found, including GSTM1, 
GSTT1, and GSTP1. Two independent studies in advanced CRC 
patients treated with oxaliplatin looked at the GST genes for pa-
tients who experienced grade 3 cumulative neuropathy. Ruzzo et al. 
described the association between the GSTP1 105 Val G/G allele 
and the development of grade 3 neuropathy from oxaliplatin treat-
ment [92]. Additionally, Lecomte and colleagues indicated that in a 
cohort of 64 patients, there was a significant association between 
the GSTP1 105 Val G/G allele and risk of developing neurotoxicity 
[112]. Other studies are ongoing and further evaluations are neces-
sary. 
3.5.2. Cell Entry Process 
 A cell entry mechanism is another process under evaluation for 
its role in platinum toxicity. As a heavy metal, platinum drugs must 
have a particular method of entering their cell of interest. Metal 
transporters, such as the copper transporters CTR1, ATP7A, and 
ATP7B, have been of particular interest [113]. Forced overexpres-
sion of human CTR1 in ovarian cancer cells increased cisplatin up-
take. CTR1 mediates cellular accumulation of platinum-containing 
drugs used in patients. For neurotoxicity to develop, the drug must 
be capable of entering its target cells to cause damage. Therefore, 
any genes or proteins involved in the transport of platinum into or 
out of cells could play a role in neurotoxicity development. How-
ever, there are no clinical studies assessing the influence of genetic 
variation in platinum transporters on patient toxicity or outcome. 
3.5.3. DNA Repair: ERCC1 
 DNA repair is an important mechanism for resistance to plati-
num-based therapy and possibly the development of neurotoxicity. 
The capacity of the cells to repair their DNA attacked by the plati-
num agent determine probably the unsuccessful in inducing apopto-
sis. After an initial no association shown between NER and chemo-
therapy neurotoxicity, ERCC1, previously described as probably 
predictive response factors, have been hypothesized to play also a 
role in the efficacy of platinum-based drugs. Among the numerous 
studies done assessing the association between nucleotide excision 
repair genes and chemotherapy clinical outcome, many have pro-
vided concrete evidence of an association, as described by Park DJ 
et al. Patients, whose response to oxaliplatin therapy was better, 
presented a lower level of neutropenia and neurotoxicity [104]. We 
need for other studies investigating a molecular process to prove it.  
 Until the concrete phenotype/genotype associations have been 
established to enable individualized therapy, we should be aware of 
the risk of the severe, life-altering side effect of toxicity until sus-
pension of treatment. Time to optimal treatment is one of the key 
factors in determining the success of therapy in patients with can-
cer. Hence, the use of biomarkers to guide current clinical practice 
is imperative to improve disease prognosis and patient tolerability. 
Though intriguing, further studies are needed before translating 
these findings into the clinical setting. 
4. CONCLUSION 
 Current data strongly supports the use of some of the biomark-
ers discussed in this article to guide CRC therapy based on inter-
individual variability. These results represents a good start toward 
the goal of bringing personalized fluoropyrimidines and oxaliplatin 
regimens to each patient with CRC, but more comprehensive and 
integrated studies are needed to make this a reality. In fact, many of 
the biomarker studies suffer from small sample sizes, retrospective 
design, ambiguous study endpoints, and non-uniform acquisition of 
source tumor material and bioassays. To make progress, it becomes 
necessary a more coordinated evaluation of these markers before 
genetic information, as a routine part of clinical CRC treatment. 
Molecular diagnostics capable of a more precise prognosis based on 
individual biomarkers are imperative to the successful clinical ad-
aptation of the field of pharmacogenetics. Use of predictive bio-
markers should be made an integral part of current clinical practice 
more frequently, and be used as an aid to clinical experience and 
expertise in making CRC patient therapy decisions. Follow-up stud-
ies are also required to identify the functional significance of the 
many mutations and polymorphic variants for response and toxicity 
that exist in the patient population during treatment. Such func-
tional information will inevitably assist in unravelling the complex 
and multifaceted mechanisms of drugs metabolism and cytotoxic-
ity. The continuing evolution of highthroughput technologies such 
previous described microarray gene profiling, proteomic profiling, 
and the newly developed metabolomics field will improve the reso-
lution and sensitivity with which we can detect such markers. The 
inclusion of pharmacogenetic biomarkers, such as those reviewed in 
this article, in the paradigm of CRC therapy will enable the deter-
mination of patients most likely to benefit from therapeutic inter-
ventions tailored specifically for them.  
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